Advertisement

Pieris Pharmaceuticals, Inc. PIRS

Set alert

Price alert · PIRS

All alert types
13.60 +13.60 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
17.96M
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-68.00
Beta
0.66
Short ratio
3.52
Inst. own
52.92%
Dividend
0.00
Ex-div date
Earnings
Nov 13, 2024
50-d avg
16.46
200-d avg
14.03
1y target
0.00

2Y chart

Chart tools
Interval

Events in this range
  • Aug 10, 2023Earnings: —; estimate -12.8; surprise —%
  • Nov 14, 2023Earnings: —; estimate -8.8; surprise —%
  • Apr 23, 2024Split: 1 for 80
  • May 15, 2024Earnings: —; estimate 0; surprise —%
  • Aug 14, 2024Earnings: —; estimate 0; surprise —%
  • Nov 13, 2024Earnings: —; estimate 0; surprise —%
Signals (92)
NameDateAgo
SMA: BearishDec 13, 20241 year ago
MACD: Sell SignalDec 13, 20241 year ago
RSI: OversoldDec 13, 20241 year ago
SMA: BearishDec 12, 20241 year ago
SMA: BullishDec 9, 20241 year ago
SMA: BearishDec 5, 20241 year ago
SMA: BullishDec 4, 20241 year ago
SMA: BearishNov 29, 20241 year ago
MACD: Buy SignalNov 25, 20241 year ago
SMA: BullishNov 22, 20241 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BullishNov 8, 20241 year ago
SMA: BearishNov 6, 20241 year ago
MACD: Sell SignalNov 6, 20241 year ago
SMA: BullishOct 31, 20242 years ago
SMA: BearishOct 30, 20242 years ago
SMA: BullishOct 23, 20242 years ago
SMA: BearishOct 21, 20242 years ago
SMA: BullishOct 17, 20242 years ago
MACD: Buy SignalOct 17, 20242 years ago
SMA: BearishOct 1, 20242 years ago
SMA: BullishSep 30, 20242 years ago
SMA: BearishSep 26, 20242 years ago
RSI: OverboughtAug 21, 20242 years ago
MACD: Sell SignalAug 12, 20242 years ago
RSI: OverboughtAug 6, 20242 years ago
SMA: BullishJul 24, 20242 years ago
SMA: BullishJul 24, 20242 years ago
RSI: OverboughtJul 24, 20242 years ago
MACD: Buy SignalJul 18, 20242 years ago
RSI: OversoldJul 8, 20242 years ago
MACD: Sell SignalJul 5, 20242 years ago
MACD: Buy SignalJun 28, 20242 years ago
RSI: OversoldJun 24, 20242 years ago
MACD: Sell SignalJun 20, 20242 years ago
RSI: OversoldJun 18, 20242 years ago
MACD: Buy SignalJun 4, 20242 years ago
MACD: Sell SignalMay 28, 20242 years ago
RSI: OversoldMay 23, 20242 years ago
MACD: Buy SignalMay 10, 20242 years ago
RSI: OversoldMay 3, 20242 years ago
SMA: BearishApr 12, 20242 years ago
SMA: BullishApr 9, 20242 years ago
SMA: BearishApr 3, 20242 years ago
MACD: Sell SignalMar 28, 20242 years ago
SMA: BullishMar 18, 20242 years ago
RSI: OverboughtMar 18, 20242 years ago
SMA: BearishMar 15, 20242 years ago
SMA: BullishMar 12, 20242 years ago
SMA: BearishMar 11, 20242 years ago
SMA: BullishMar 7, 20242 years ago
SMA: BearishMar 6, 20242 years ago
SMA: BullishMar 1, 20242 years ago
SMA: BearishFeb 29, 20242 years ago
SMA: BullishFeb 28, 20242 years ago
SMA: BearishFeb 22, 20242 years ago
SMA: BullishFeb 21, 20242 years ago
MACD: Buy SignalFeb 21, 20242 years ago
MACD: Sell SignalFeb 12, 20242 years ago
SMA: BearishFeb 5, 20242 years ago
SMA: BullishJan 31, 20242 years ago
MACD: Buy SignalDec 22, 20232 years ago
RSI: OversoldDec 11, 20232 years ago
RSI: OversoldNov 22, 20232 years ago
MACD: Sell SignalNov 16, 20232 years ago
MACD: Buy SignalNov 2, 20232 years ago
RSI: OversoldOct 27, 20233 years ago
RSI: OversoldOct 23, 20233 years ago
MACD: Sell SignalOct 12, 20233 years ago
SMA: BearishOct 11, 20233 years ago
MACD: Buy SignalOct 10, 20233 years ago
SMA: BullishOct 3, 20233 years ago
SMA: BearishOct 2, 20233 years ago
MACD: Sell SignalSep 7, 20233 years ago
RSI: OverboughtAug 22, 20233 years ago
SMA: BullishAug 21, 20233 years ago
MACD: Buy SignalJul 12, 20233 years ago
SMA: BearishJun 21, 20233 years ago
MACD: Sell SignalJun 21, 20233 years ago
RSI: OversoldJun 21, 20233 years ago
SMA: BullishJun 2, 20233 years ago
MACD: Buy SignalMay 31, 20233 years ago
MACD: Sell SignalMay 30, 20233 years ago
MACD: Buy SignalApr 19, 20233 years ago
RSI: OversoldApr 6, 20233 years ago
MACD: Sell SignalMar 29, 20233 years ago
MACD: Buy SignalMar 28, 20233 years ago
SMA: BearishMar 9, 20233 years ago
MACD: Sell SignalFeb 7, 20233 years ago
RSI: OverboughtFeb 2, 20233 years ago
RSI: OverboughtJan 25, 20233 years ago
RSI: OverboughtJan 9, 20233 years ago

Key statistics

Market cap
17.96M
Enterprise value
1.33M
Trailing P/E
0.00
Forward P/E
-68.00
PEG ratio
0.00
Price / sales
0.86
Price / book
0.63
EPS (TTM)
-12.11
Beta
0.66
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-114.12%
Revenue (TTM)
20.87M
Revenue growth
0.00%
Free cash flow
-25.49M
Total cash
19.73M
Total debt
0
Return on equity
-80.46%
Shares outstanding
1.32M
Short % of float
2.12%
50-day average
16.46
200-day average
14.03

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Nov 13, 2024

Expected Nov 13, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
PIRS Revenue — quarterly 0
2020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-30
PIRS Net income — quarterly -3.59M
2020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-30
PIRS EPS — quarterly -2.76
2020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-30

Earnings

PIRS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.00———
Aug 14, 2024Jun 1, 20240.00———
May 15, 2024Mar 1, 20240.00———
Mar 29, 2024Dec 1, 2023-9.60———
Nov 14, 2023Sep 1, 2023-8.80———
Aug 10, 2023Jun 1, 2023-12.80———

Upgrades / downgrades

PIRS analyst upgrades and downgrades
DateFirmActionFromTo
Mar 13, 2020BairdupNeutralOutperform
Jul 30, 2019BairddownOutperformNeutral
May 14, 2019Bairdinit—Outperform
May 4, 2018Cowen & Co.init—Outperform
Mar 19, 2018Evercore ISI Groupinit—Outperform
Mar 19, 2018Jefferiesinit—Buy

About Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
pieris.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on PIRS — it syncs with the Stock Master app.

Insider holders

PIRS insider holders
InsiderRelationLatest transactionDateShares held
KIRITSY CHRISTOPHER PDirectorPurchaseMay 24, 202320,000

Institution ownership

PIRS institution ownership
Holder% heldSharesValueReported
BVF Inc.19.51%257,6263.50MSep 29, 2024
Adar1 Capital Management, LLC 10.96%144,6411.97MSep 29, 2024
BML Capital Management, LLC3.19%42,130572.97KSep 29, 2024
Lynx1 Capital Management Lp2.84%37,436509.13KSep 29, 2024
Renaissance Technologies, LLC2.44%32,171437.52KSep 29, 2024
CM Management, LLC1.70%22,500306.00KSep 29, 2024

Fund ownership

PIRS fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.84%11,069150.54KSep 29, 2024
Fidelity Extended Market Index Fund0.54%7,16197.39KOct 30, 2024
Fidelity Total Market Index Fund0.14%1,88225.59KOct 30, 2024
Fidelity Series Total Market Index Fund0.14%1,81524.68KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%2823.83KOct 30, 2024
Advertisement